We use cookies on our site to track usage and preferences. Learn more

CN Bio FDA collaboration expanded

  • Date 11 May 2021

The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications.

CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using the PhysioMimix™ MPS platform, to appraise the system’s use for the evaluation of inhaled drug products and assessing additional applications for CN Bio’s liver model.

Read more

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

Read more